Drug Profile
Research programme: inhaled respiratory infection therapeutics - Pulmocide
Alternative Names: PC 1244Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Pulmocide
- Class Antivirals
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Invasive bronchopulmonary aspergillosis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Invasive bronchopulmonary aspergillosis in United Kingdom (Inhalation) (Pulmocide pipeline, April 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Invasive-bronchopulmonary-aspergillosis in United Kingdom (Inhalation)
- 16 May 2018 Pulmocide has patent protection for PC 1244 in USA